JPMorgan downgrades this drugmaker, cuts price target by 19% citing growth challenges

Of the eight analysts who have coverage on the Abbott India stock, six have a ‘buy’ rating, while one each have ‘hold’ and ‘sell’ ratings.

Leave a Reply

Your email address will not be published. Required fields are marked *